Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 3/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115442 | 0.87 | ALDH1A1 (0.46) | ALDH1A1HPGDACE2XDHF11 | |
| SCHEMBL30211966 | 0.86 | ACE2 (0.51) | ALDH1A1HPGDACE2XDHGRM1 | |
| SCHEMBL3908449 | 0.86 | ACE2 (0.51) | ALDH1A1HPGDACE2XDHGRM1 | |
| SCHEMBL1872491 | 0.79 | XDH (0.60) | ALDH1A1HPGDXDHF11KMT2A | |
| SCHEMBL29472005 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HPGDXDHMRGPRX4 | |
| SCHEMBL4844022 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HPGDXDHMRGPRX4 | |
| SCHEMBL13816269 | 0.77 | ACE2 (0.61) | ALDH1A1ACE2GABRA1GABRB1GRM1 | |
| SCHEMBL996704 | 0.77 | MRGPRX4 (0.56) | ALDH1A1HPGDMRGPRX4GRM1MEN1 | |
| SCHEMBL23265293 | 0.76 | RXRA (0.48) | ALDH1A1HPGDMEN1KMT2ATDP1 | |
| SCHEMBL403398 | 0.76 | XDH (0.67) | ALDH1A1HPGDXDHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | ALDH1A1 4019/4885HPGD 4141/4885ACE2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.